Skip to main content

Treatment Clinical Trials for Myelodysplastic Syndrome

Review the myelodysplastic syndrome treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 176-200 of 217

HA-1 T TCR T cell Immunotherapy for the Treatment of Patients with Relapsed or Refractory Acute Leukemia after Donor Stem Cell Transplant
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
CAR T-cell Therapy (CD70-CAR) for the Treatment of Hematological Malignancies in Pediatric Patients
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Adding Hyperbaric Oxygen Therapy to Allogeneic Stem Cell Transplant for Treating Hematologic Cancers
Status: Active
Location: University of Rochester, Rochester, New York
Azacitidine and Decitabine for the Treatment of Myelodysplastic Syndrome or Other Related Cancers
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients with Multiple Myeloma, Plasma Cell Leukemia or Low Risk Myelodysplastic Syndrome
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Status: Active
Location: See ClinicalTrials.gov
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Status: Active
Location: See ClinicalTrials.gov
Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
Status: Active
Location: See ClinicalTrials.gov
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Status: Active
Location: See ClinicalTrials.gov
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
Status: Active
Location: See ClinicalTrials.gov
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: See ClinicalTrials.gov
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Status: Active
Location: See ClinicalTrials.gov
KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
Status: Enrolling by Invitation
Location: 8 locations
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Status: Enrolling by Invitation
Location: 2 locations
TCRalpha/beta and CD19+ depleted Hematopoietic Stem Cell Transplant from Closely Matched Unrelated Donors or Haploidentical Related donors for Blood Disorders in Children and Young Adults
Status: Approved
Location: 2 locations
Cell Therapy (CIML NK Cells) for the Treatment of Recurrent Myeloid Disease after Donor Blood Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: 3 locations
Venetoclax in Combination with Conventional Chemotherapy for the Treatment of Pediatric Patients with Acute Myeloid Leukemia
Status: Temporarily Closed to Accrual
Location: 9 locations